Ernexa Therapeutics Inc.
13F holders, Q3 2025 (September 30)14holders +2
3new positions
1sold out
$1.09avg. 13F price*
At the end of Q3 2025, 14 institutions reported holding Ernexa Therapeutics Inc. in their 13F filings, up 2 from Q2 2025. 3 opened new positions and 1 sold out. The largest holders were Corient Private Wealth LP ($480K), Susquehanna International Group, LLP ($34K) and Geode Capital Management, LLC ($22K).
- Company
- Ernexa Therapeutics Inc.
- CUSIP
- 114082308
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $52K |
| Exits | 1 | $1K |
All 13F filers, Q2 2025 → Q3 2025: 468,142 shares bought and 1,025 shares sold, net +467,117 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Corient Private Wealth LP | 0.00% | Add +2400.1% | 438,092 | $480K |
| Susquehanna International Group, LLP | 0.00% | New | 30,854 | $34K |
| Geode Capital Management, LLC | 0.00% | Add +1.9% | 20,453 | $22K |
| Vanguard Group Inc. | 0.00% | New | 11,147 | $12K |
| Sippican Capital Advisors | 0.01% | No change | 10,000 | $11K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 5,182 | $6K |
| BlackRock, Inc. | 0.00% | No change | 820 | $898 |
| Assetmark, Inc. | 0.00% | No change | 133 | $146 |
| EverSource Wealth Advisors, LLC | 0.00% | No change | 116 | $127 |
| Morgan Stanley | 0.00% | Reduce -86.1% | 77 | $84 |
| Bank of America Corp. | 0.00% | Add +57.1% | 33 | $36 |
| BNP Paribas Financial Markets | 0.00% | No change | 10 | $11 |
| Montag A & Associates Inc. | 0.00% | No change | 8 | $9 |
| Activest Wealth Management | 0.00% | No change | 3 | $3 |
"% of holder's portfolio" is ERNEXA THERAPEUTICS INC's weight in each manager's 13F, not the share of Ernexa Therapeutics Inc. the manager owns.